Abstract:Biologically active proteins/regions without stable structure (i.e., intrinsically disordered proteins and regions (IDPs and IDRs)) are commonly found in all proteomes. They have a unique functional repertoire that complements the functionalities of ordered proteins and domains. IDPs/IDRs are multifunctional promiscuous binders capable of folding at interaction with specific binding partners on a template- or context-dependent manner, many of which undergo liquid-liquid phase separation, leading to the formation of membrane-less organelles and biomolecular condensates. Many of them are frequently related to the pathogenesis of various human diseases. All this defines IDPs/IDRs as attractive targets for the development of novel drugs. However, their lack of unique structures, multifunctionality, binding promiscuity, and involvement in unusual modes of action preclude direct use of traditional structure-based drug design approaches for targeting IDPs/IDRs, and make disorder-based drug discovery for these "protein clouds" challenging. Despite all these complexities there is continuing progress in the design of small molecules affecting IDPs/IDRs. This article describes the major structural features of IDPs/IDRs and the peculiarities of the disorder-based functionality. It also discusses the roles of IDPs/IDRs in various pathologies, and shows why the approaches elaborated for finding drugs targeting ordered proteins cannot be directly used for the intrinsic disorder-based drug design, and introduces some novel methodologies suitable for these purposes. Finally, it emphasizes that regardless of their multifunctionality, binding promiscuity, lack of unique structures, and highly dynamic nature, "protein clouds" are principally druggable. Significance Statement Intrinsically disordered proteins and regions are highly abundant in nature, have multiple important biological functions, are commonly involved in the pathogenesis of a multitude of human diseases, and are therefore considered as very attractive drug targets. Although dealing with these unstructured multifunctional protein/regions is a challenging task, multiple innovative approaches have been designed to target them by small molecules.

Which cryptic sites are feasible drug targets?

CrypToth: Cryptic pocket detection through mixed-solvent molecular dynamics simulations based topological data analysis

Does Drug-Target Have A Likeness?

Conservation of Potentially Druggable Cavities in Intrinsically Disordered Proteins

Binding site detection and druggability prediction of protein targets for structure-based drug design.

Binding Cavities and Druggability of Intrinsically Disordered Proteins.

Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform

Exploration of cryptic pockets using enhanced sampling along normal modes: A case study of KRAS G12D

Comprehensive detection and characterization of human druggable pockets through novel binding site descriptors

Comprehensive detection and characterization of human druggable pockets through binding site descriptors

Identification of Cavities on Protein Surface Using Multiple Computational Approaches for Drug Binding Site Prediction

Exploring Druggable Binding Sites on the Class A GPCRs Using the Residue Interaction Network and Site Identification by Ligand Competitive Saturation

Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets

SWISH-X, an Expanded Approach to Detect Cryptic Pockets in Proteins and at Protein-Protein Interfaces

Network-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification

DrugProtAI: A guide to the future research of investigational target proteins

Implications of protein flexibility for drug discovery

Multiple target-based pharmacophore design from active site structures

Combined physics- and machine-learning-based method to identify druggable binding sites using SILCS-Hotspots

Druggable exosites of the human kino-pocketome

How to drug a cloud? Targeting intrinsically disordered proteins